BIOMAT Database Logo BIOMAT Database Logo

Graves' disease after 131I therapy for toxic nodule. 2001

J Soule, and R Mayfield
Medical University of South Carolina, Division of Endocrinology, Diabetes and Medical Genetics, Charleston 29425, USA. soulej@musc.edu

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013972 Thyrotropin A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity. Thyroid-Stimulating Hormone,TSH (Thyroid Stimulating Hormone),Thyreotropin,Thyrotrophin,Hormone, Thyroid-Stimulating,Thyroid Stimulating Hormone
D013974 Thyroxine The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. L-Thyroxine,Levothyroxine,T4 Thyroid Hormone,3,5,3',5'-Tetraiodothyronine,Berlthyrox,Dexnon,Eferox,Eltroxin,Eltroxine,Euthyrox,Eutirox,L-3,5,3',5'-Tetraiodothyronine,L-Thyrox,L-Thyroxin Henning,L-Thyroxin beta,L-Thyroxine Roche,Levo-T,Levothroid,Levothyroid,Levothyroxin Deladande,Levothyroxin Delalande,Levothyroxine Sodium,Levoxine,Levoxyl,Lévothyrox,Novothyral,Novothyrox,O-(4-Hydroxy-3,5-diiodophenyl) 3,5-diiodo-L-tyrosine,O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine,Oroxine,Sodium Levothyroxine,Synthroid,Synthrox,Thevier,Thyrax,Thyroxin,Tiroidine,Tiroxina Leo,Unithroid,L Thyrox,L Thyroxin Henning,L Thyroxin beta,L Thyroxine,L Thyroxine Roche,Levo T,Thyroid Hormone, T4
D016606 Thyroid Nodule A small circumscribed mass in the THYROID GLAND that can be of neoplastic growth or non-neoplastic abnormality. It lacks a well-defined capsule or glandular architecture. Thyroid nodules are often benign but can be malignant. The growth of nodules can lead to a multinodular goiter (GOITER, NODULAR). Nodule, Thyroid,Nodules, Thyroid,Thyroid Nodules

Related Publications

J Soule, and R Mayfield
[Thyroid nodule after radioiodine (131I) therapy for Graves' disease].
March 1984, Kaku igaku. The Japanese journal of nuclear medicine,
J Soule, and R Mayfield
Vocal cord paralysis after 131I therapy for solitary toxic nodule.
March 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
J Soule, and R Mayfield
[Serum free thyroxine after 131I therapy for Graves' disease (author's transl)].
December 1981, Kaku igaku. The Japanese journal of nuclear medicine,
J Soule, and R Mayfield
Thyroid function in patients with Graves' disease long after 131I therapy.
July 1980, Fukuoka igaku zasshi = Hukuoka acta medica,
J Soule, and R Mayfield
Compensated low-dose 131I therapy of Graves' disease.
October 1977, Annals of internal medicine,
J Soule, and R Mayfield
Histologic changes in Graves' thyroid gland after 131I therapy for hyperthyroidism.
June 1992, Acta pathologica japonica,
J Soule, and R Mayfield
Graves' ophthalmopathy and 131I therapy.
December 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR),
J Soule, and R Mayfield
Outcome following standardized 185 MBq dose 131I therapy for Graves' disease.
May 1988, Clinical endocrinology,
J Soule, and R Mayfield
Follow-up of compensated low-dose 131I therapy for Graves' disease.
December 1984, The New England journal of medicine,
J Soule, and R Mayfield
The development of a solitary toxic thyroid nodule following Graves' disease.
October 1988, Clinical nuclear medicine,
Copied contents to your clipboard!